Karyopharm Therapeutics (NASDAQ:KPTI) Receives Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note published on Monday,Benzinga reports. Piper Sandler currently has a $8.00 price objective on the stock, down from their prior price objective of $12.00.

Several other equities research analysts also recently commented on the company. The Goldman Sachs Group set a $12.00 price objective on Karyopharm Therapeutics in a report on Wednesday, December 17th. Cantor Fitzgerald initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating for the company. Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, March 25th. Rodman & Renshaw raised shares of Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.29.

Karyopharm Therapeutics Stock Down 3.3%

NASDAQ KPTI opened at $5.30 on Monday. The firm has a market capitalization of $97.20 million, a PE ratio of -0.32 and a beta of 0.13. The stock’s 50 day moving average is $7.70 and its 200 day moving average is $6.82. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million. On average, research analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Corient Private Wealth LLC purchased a new stake in Karyopharm Therapeutics in the fourth quarter valued at $74,000. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. State Street Corp lifted its holdings in shares of Karyopharm Therapeutics by 27.2% in the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after buying an additional 12,600 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth about $95,000. Finally, XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics during the second quarter worth about $56,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.